Fondaparinux sodium: A selective inhibitor of factor Xa
Fondaparinux sodium: A selective inhibitor of factor Xa
复制标题
DOI：
10.1093/ajhp/58.suppl_2.s14
复制
发表时间：
2001-11-01
影响因子：
2.7
通讯作者：
Bauer, KA
中科院分区：
文献类型：
--
作者：
Bauer, KA
磺达肝癸钠是第一种选择性靶向Xa因子的新型抗凝剂，其药理作用和作用机制已被描述。它具有线性、剂量依赖性药代动力学特征，提供了高度可预测的反应。它具有100%的生物利用度，起效迅速，半衰期为14至16小时，可在24小时内持续发挥抗血栓活性。药物不影响凝血酶原时间或活化部分凝血活酶时间，也不影响血小板功能或聚集。对肝素诱导的血小板减少症患者的研究表明，该药物与肝素抗体的体外交叉反应无关，磺达肝癸钠似乎符合理想抗血栓药物的标准：与现有药物相当或更好的有效性，低出血风险，不需要实验室监测，每日一次给药。
The pharmacology and mechanism of action of fondaparinux sodium are described.Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. It has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. It is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation. Studies in patients with confirmed heparin-induced thrombocytopenia demonstrate that the drug is not associated with in vitro cross-reactivity to heparin antibodies.Fondaparinux sodium appears to meet the criteria for an ideal antithrombotic agent: equal or better effectiveness than currently available agents, a low bleeding risk, no need for laboratory monitoring, and once-daily administration.